Resveratrol Induces Premature Senescence in Lung Cancer Cells via ROS-Mediated DNA Damage | PLOS ONE
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer - ScienceDirect
AEACaP and LuCE host webinar on “ROS-1 Lung Cancer Patients”
Caveolin-1 Regulates Endothelial Adhesion of Lung Cancer Cells via Reactive Oxygen Species-Dependent Mechanism | PLOS ONE
Agents Targeting ROS1 Gain Traction in NSCLC
Cancers | Free Full-Text | Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
ROS1 Mutation in Lung Cancer - What is ROS1 Mutation in Lung Cancer?
RET, ROS1 and ALK fusions in lung cancer | Nature Medicine
Type of ROS1 rearrangement in nonsmall cell lung cancer. Exons 32, 34... | Download Scientific Diagram
New Targets in Non–Small Cell Lung Cancer | Oncohema Key
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers - ScienceDirect
Frontiers | Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
ROS in cancer therapy: the bright side of the moon | Experimental & Molecular Medicine
Recent Advances in Targeting ROS1 in Lung Cancer - ScienceDirect
ROS1 - Wikipedia
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 | NEJM
Frontiers | Comparison of COVID-19 and Lung Cancer via Reactive Oxygen Species Signaling
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer | NEJM
Detection of ROS1 rearrangement in non-small cell lung cancer: current | LCTT
PDF] Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer | Semantic Scholar